Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-20-019221
Filing Date
2020-04-28
Accepted
2020-04-28 16:14:04
Documents
8
Effectiveness Date
2020-04-28

Document Format Files

Seq Description Document Type Size
1 DEFA14A 2020 snss-defa14a_20200616.htm DEFA14A 111479
2 GRAPHIC g4oooku1kbg1000001.jpg GRAPHIC 1362
3 GRAPHIC g4oooku1kbg1000007.jpg GRAPHIC 1035
4 GRAPHIC g4oooku1kbg1000003.jpg GRAPHIC 2391
5 GRAPHIC g4oooku1kbg1000004.jpg GRAPHIC 1062
6 GRAPHIC g4oooku1kbg1000002.jpg GRAPHIC 2391
7 GRAPHIC g4oooku1kbg1000005.jpg GRAPHIC 2391
8 GRAPHIC g4oooku1kbg1000006.jpg GRAPHIC 1063
  Complete submission text file 0001564590-20-019221.txt   129847
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51531 | Film No.: 20825154
SIC: 2834 Pharmaceutical Preparations